These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 24964990)

  • 1. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody.
    Geisbert TW; Mire CE; Geisbert JB; Chan YP; Agans KN; Feldmann F; Fenton KA; Zhu Z; Dimitrov DS; Scott DP; Bossart KN; Feldmann H; Broder CC
    Sci Transl Med; 2014 Jun; 6(242):242ra82. PubMed ID: 24964990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge.
    Bossart KN; Geisbert TW; Feldmann H; Zhu Z; Feldmann F; Geisbert JB; Yan L; Feng YR; Brining D; Scott D; Wang Y; Dimitrov AS; Callison J; Chan YP; Hickey AC; Dimitrov DS; Broder CC; Rockx B
    Sci Transl Med; 2011 Oct; 3(105):105ra103. PubMed ID: 22013123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates.
    Zeitlin L; Cross RW; Woolsey C; West BR; Borisevich V; Agans KN; Prasad AN; Deer DJ; Stuart L; McCavitt-Malvido M; Kim DH; Pettitt J; Crowe JE; Whaley KJ; Veesler D; Dimitrov A; Abelson DM; Geisbert TW; Broder CC
    Sci Transl Med; 2024 Apr; 16(741):eadl2055. PubMed ID: 38569014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.
    Bossart KN; Rockx B; Feldmann F; Brining D; Scott D; LaCasse R; Geisbert JB; Feng YR; Chan YP; Hickey AC; Broder CC; Feldmann H; Geisbert TW
    Sci Transl Med; 2012 Aug; 4(146):146ra107. PubMed ID: 22875827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection.
    Bossart KN; Zhu Z; Middleton D; Klippel J; Crameri G; Bingham J; McEachern JA; Green D; Hancock TJ; Chan YP; Hickey AC; Dimitrov DS; Wang LF; Broder CC
    PLoS Pathog; 2009 Oct; 5(10):e1000642. PubMed ID: 19888339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection.
    Geisbert TW; Daddario-DiCaprio KM; Hickey AC; Smith MA; Chan YP; Wang LF; Mattapallil JJ; Geisbert JB; Bossart KN; Broder CC
    PLoS One; 2010 May; 5(5):e10690. PubMed ID: 20502528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy.
    Mire CE; Satterfield BA; Geisbert JB; Agans KN; Borisevich V; Yan L; Chan YP; Cross RW; Fenton KA; Broder CC; Geisbert TW
    Sci Rep; 2016 Aug; 6():30916. PubMed ID: 27484128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection.
    Mire CE; Chan YP; Borisevich V; Cross RW; Yan L; Agans KN; Dang HV; Veesler D; Fenton KA; Geisbert TW; Broder CC
    J Infect Dis; 2020 May; 221(Suppl 4):S471-S479. PubMed ID: 31686101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease.
    Monath TP; Nichols R; Feldmann F; Griffin A; Haddock E; Callison J; Meade-White K; Okumura A; Lovaglio J; Hanley PW; Clancy CS; Shaia C; Rida W; Fusco J
    Front Immunol; 2023; 14():1216225. PubMed ID: 37731485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.
    Mire CE; Versteeg KM; Cross RW; Agans KN; Fenton KA; Whitt MA; Geisbert TW
    Virol J; 2013 Dec; 10():353. PubMed ID: 24330654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.
    Zhu Z; Bossart KN; Bishop KA; Crameri G; Dimitrov AS; McEachern JA; Feng Y; Middleton D; Wang LF; Broder CC; Dimitrov DS
    J Infect Dis; 2008 Mar; 197(6):846-53. PubMed ID: 18271743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease.
    Mire CE; Geisbert JB; Agans KN; Versteeg KM; Deer DJ; Satterfield BA; Fenton KA; Geisbert TW
    Emerg Infect Dis; 2019 Jun; 25(6):1144-1152. PubMed ID: 31107231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge.
    Yoneda M; Georges-Courbot MC; Ikeda F; Ishii M; Nagata N; Jacquot F; Raoul H; Sato H; Kai C
    PLoS One; 2013; 8(3):e58414. PubMed ID: 23516477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
    Foster SL; Woolsey C; Borisevich V; Agans KN; Prasad AN; Deer DJ; Geisbert JB; Dobias NS; Fenton KA; Cross RW; Geisbert TW
    Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2200065119. PubMed ID: 35286211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.
    DeBuysscher BL; Scott D; Marzi A; Prescott J; Feldmann H
    Vaccine; 2014 May; 32(22):2637-44. PubMed ID: 24631094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking.
    Tit-Oon P; Tharakaraman K; Artpradit C; Godavarthi A; Sungkeeree P; Sasisekharan V; Kerdwong J; Miller NL; Mahajan B; Khongmanee A; Ruchirawat M; Sasisekharan R; Fuangthong M
    Sci Rep; 2020 Oct; 10(1):18256. PubMed ID: 33106487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein.
    Dong J; Cross RW; Doyle MP; Kose N; Mousa JJ; Annand EJ; Borisevich V; Agans KN; Sutton R; Nargi R; Majedi M; Fenton KA; Reichard W; Bombardi RG; Geisbert TW; Crowe JE
    Cell; 2020 Dec; 183(6):1536-1550.e17. PubMed ID: 33306954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A highly effective ferritin-based divalent nanoparticle vaccine shields Syrian hamsters against lethal Nipah virus.
    Yin C; Yao YF; Yang P; Liu H; Gao G; Peng Y; Chen M; Lu M; Zhang X; Guo W; Zhang Z; Hu X; Yuan Z; Shan C
    Front Immunol; 2024; 15():1387811. PubMed ID: 38911870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development.
    Loomis RJ; Stewart-Jones GBE; Tsybovsky Y; Caringal RT; Morabito KM; McLellan JS; Chamberlain AL; Nugent ST; Hutchinson GB; Kueltzo LA; Mascola JR; Graham BS
    Front Immunol; 2020; 11():842. PubMed ID: 32595632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme-Linked Immunosorbent Assay Using Henipavirus-Receptor EphrinB2 and Monoclonal Antibodies for Detecting Nipah and Hendra Viruses.
    Zhu W; Smith G; Pickering B; Banadyga L; Yang M
    Viruses; 2024 May; 16(5):. PubMed ID: 38793674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.